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Abstract  
Introduction: Amiodarone is associated with significant long-lasting adverse drug 
reactions (ADRs). Guidelines recommend laboratory monitoring during long-term 
use. However, data of compliance with laboratory monitoring is lacking.   
Aims: The aim of this study was to assess laboratory monitoring of liver and thyroid 
function during amiodarone prescribing from 1989-2011 in the Tayside, UK, 
population (approximately 400,000) in relation to National guidelines recommending 
laboratory monitoring every 6 months. We also report the population-level incidence 
of abnormal liver and thyroid function in relation to total exposure of amiodarone.  
Methods: Utilising well-established record linkage database, a longitudinal 
retrospective analysis of 1413 patients on long-term amiodarone was carried out, 
analysing prescribing, biochemical and clinical data.  
Results: Forty-six per cent (46%), 28% and 21% of patients underwent liver, thyroid, 
and combined testing respectively in accordance with guideline recommendations. 
Thirteen per cent and 17% of patients did not have any ALT or TSH testing, 
respectively. During follow-up, 117 (9.5%) patients had an ALT 3xULN and 16% 
patients had an abnormal TSH, (n=125, <0.4mU/l and n=28, >10mU/l). One-hundred 
and forty patients (10%) required thyroxine replacement therapy and 40 (3%) 
required on hyperthyroid medication. Total amiodarone exposure increased the 
likelihood of abnormal biochemical testing 2.5-fold after 4 years therapy for liver and 
thyroid function (p<0.0005) 
Conclusion: In this population-based study, adherence to laboratory monitoring 
guidelines was sub-optimal. There was a positive correlation with total amiodarone 
exposure and biochemical abnormalities and development of thyroid disease 
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compared to the general population, highlighting the need for improvement and 
continued amiodarone monitoring.  
 
Keywords: amiodarone, prescribing, hepatotoxicity, monitoring, thyroid disease, 
adverse drug reactions 
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Introduction 
Amiodarone is the most prescribed anti-arrhythmic drug worldwide (1), in spite of its 
high incidence of side effects. Its adverse effects include numerous organ toxicities 
with liver, thyroid, lungs and eyes being most notably affected (2). The incidence of 
amiodarone-induced toxicity is reported to be relatively high with thyroid toxicity in 1-
22%, hepatic toxicity in 15-50% and pulmonary toxicity in 2-7%(3). Amiodarone’s 
long half-life in conjunction with this high incidence of toxicities makes careful patient 
monitoring relevant(3) and cost effective(4). As such, guidelines have been 
developed,(5-8), recommending laboratory monitoring liver and thyroid function at 
baseline and then testing 6 monthly thereafter. 
 
In the era of these recommendations, implementation of monitoring in the United 
Kingdom has not been previously reported. The aim of this population based 
longitudinal study was to assess monitoring in patients on long-term amiodarone in 
the Tayside population (approximately 400,000) in United Kingdom Tayside between 
1989-2011 and to determine the incidence of abnormal liver function tests and 
thyroid dysfunction in relation to total exposure of amiodarone, using the record-
linkage Health Informatics Centre (HIC) dispensed prescription database in Tayside. 
 
Methods  
We conducted a retrospective observational population based study of patients who 
had been prescribed amiodarone using record linked administrative data. Using the 
unique Scottish patient identification Community Health Index (CHI) number, 
anonymised prescription data was linked utilising the well-established Health 
Informatics Centre (HIC) record linkage database in Tayside to demographic and 
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laboratory results in order to obtain information regarding prescription and monitoring 
of each patient(9). Indication for amiodarone was derived from Scottish Morbidity 
Record General / Acute and Inpatient Day Case (SMR01) data regarding primary and 
co-morbid conditions (identified by ICD-9 codes until 1997 and ICD-10 codes after 
1997). All data and access to the extensive clinical NHS Tayside datasets was 
supplied and organised by HIC. The data was accessed and analysed by a secure 
remote research portal, “Safehaven®”, after Caldicott approval.  
 
Patient identification 
Using the prescription-record linkage database, all patients who were prescribed 
amiodarone over the 22 years were identified. Long-term was defined as exposure ≥ 
6 months (168 days) with regular prescriptions (time between two collected 
prescriptions ≤3months).  
Amiodarone laboratory monitoring processes was assessed for the following: 
Baseline evaluation (6 months before or one month of the first prescription) 
Baseline testing was defined as blood tests 6 months before or one month after 
commencing amiodarone. The test with closest temporal proximity to the 
commencement of amiodarone was used to identify patients with abnormal liver 
or/and thyroid function. Patient with a baseline test 3 times the upper limit of normal 
(3xULN) were excluded.  
Surveillance. Assessment of 6 monthly monitoring  
Monitoring requirements were presumed to end once a patient stopped amiodarone 
medication. Frequency of testing was performed by analysing the number of 
biochemical tests that were performed during the duration of amiodarone therapy. 
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Tests performed <30 days apart were not included in analysis. A mean number of 
days between testing of ≤6months was classed as adequate monitoring.  
 
Case Definitions of Laboratory Adverse Drug Reactions 
The upper limit of normal (ULN) of alanine aminotransferase (ALT) was 40 U/L 
(Biochemistry Service, Ninewells Hospital, Dundee). 3xULN was regarded as an 
adverse drug reaction (ADR) for ALT.  
Normal reference range for Thyroid Stimulating Hormone (TSH) was defined 
between 0.4 and 4.5 mU/L. Hyperthyroidism was classified as TSH <0.4mU/L and 
>10mU/L as overt hypothyroidism (10). TSH results from the 3 month period after 
starting amiodarone were excluded as TSH can transiently increase with amiodarone 
(11). Patients prescribed thyroxine were excluded from further analysis of 
biochemical abnormalities. A prescription of thyroxine (after 6 months of starting 
amiodarone) was deemed an ADR. For comparison, the incidence of thyroid 
abnormalities during amiodarone therapy was compared to that reported from a large 
epidemiological study from the same population (The Thyroid Epidemiology, Audit & 
Research Study, TEARS),(12). 
Total amiodarone exposure (dose x duration) was calculated from prescription dose, 
frequency of dosing and number of prescriptions using SPSS statistical software 
(version 18, SPSS, Chicago, USA). Total exposure was calculated and grouped into 
years’ on equivalent to 200mg daily (OD) dosing. 
Statistical Analysis 
Normally distributed logarithmic data was analysed with One-way ANOVA (Analysis 
of Variance) and post-hoc analysis (using Scheffe’s method of multiple comparisons). 
Correlation of non-normally distributed data was analysed by Spearman’s rank 
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correlation coefficient and non-parametric data was analysed by Chi-squared 
analysis. Statistical analysis was performed using SPSS statistical software (version 
18, SPSS, Chicago, USA). 
 
Results 
Patient demographics:  
Fig.ure 1 shows the consort figure that identified 1413 patients on amiodarone for 
more than 6 months between 03/01/1989 and 15/09/2011 for analysis. The patient 
demographics are shown in Table 1. The study population was predominantly male 
(57%) and elderly (mean age 71 years) with 710% of patients treated with 
amiodarone 200mg OD (Table 1). 
 
Amiodarone prescribing 
Amiodarone prescribing, grouped into 5-year periods, increased from 186 (13% of 
the total number of patients in the study) in 1989-1994 to 489 patients (35%) in 2000-
2005 (Table 2Fig. 2). Thereafter, amiodarone prescribing fell to 21% (300 patients). 
The indication for amiodarone was available in 1169 (83%) patients: 67% for atrial 
fibrillation; 9% for ventricular tachycardia; 3% for supraventricular tachycardia 
(unspecified); 3% for atrial fibrillation and ventricular tachycardia combined; and 1% 
for unspecified tachycardia. In 244 (17%) patients no diagnosis was available. The 
median daily dose of amiodarone was 200mg and the median total exposure dose 
was 14,600mg, equivalent to 1.95 years worth of 200mg OD.  
 
Monitoring 
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Liver dysfunction monitoring: Of the 1413 patients, 180 (13%) patients had no ALT 
testing. 1233 (87%) had ALT tested at least once between one month of starting 
amiodarone to discontinuation and 1046 (74%) patients had more than one test.  
Adequate ALT monitoring occurred in 644 (46%), with 644 (46%) of patients were 
adequately monitored for ALT every 6 months. 305 patients were tested for ALT 
yearly. The median number of days between testing was 153 days (~5 months) 
(range 32 days to 7.7 years).  
TSH monitoring: 413 (29%) patients on thyroxine were excluded form the analysis, 
leaving 1000 (71%) patients not prescribed thyroxine: 172 (17%) never had thyroid 
function testing; 828 (83%) patients had TSH tested at least once and 623 (62%) had 
more than one TSH test. Of the 1000 patients studied, 277 (28%) patients were 
adequately monitored at least 6 monthly, 220 (22%) were monitored yearly. The 
median number of days between testing was 202 days (~7 months) (range 32 days – 
8.3 years).  
Combined ALT & TSH monitoring: 562 (56%) patients had both ALT and TSH tested. 
Only 211 patients were adequately monitored (21% of 1000) every 6 months; . 424 
(42%) patients had both tests performed yearly. 
 
The 211 patients monitored for both ALT and TSH as per guidelines were grouped 
into 5-year periods of when they started amiodarone (Table 2Fig. 2). Monitoring for 
liver and thyroid toxicity has improved over the last twenty years, from 7.5% of 
patients in 1989-1994, to 22.3% of patients in 2005-2011 (p<0.001). 
 
Abnormal Laboratory Data 
Abnormal ALT 
Page 8 of 26Cardiovascular Therapeutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
966 (68%) patients had a Bbaseline ALT testing was performed in 966 (68%) 
patients. P18 patients with a baseline test >3xULN, n=18, and were excluded leaving 
1226 patients analysed for abnormal ALT levels. 117 (9.5%) patients developed 
Aabnormal ALT of 3xULN occurred in 117 (9.5%) patients. 180 (13%) patients did 
not have ALT monitored. 
Total exposure to amiodarone and abnormal ALT  
The median total exposure for patients with a result >3xULN was 244,000mg (3.3 
years’ worth of 200mg OD) ranging from 36,800mg (184 days of 200mg OD) to 
2,308,000mg (11,540 days of 200mg daily). The majority of patients were not on 
amiodarone for longer than 4 years’ of 200mg OD equivalent, (Fig. 23). 1048 (74%) 
1048 (74%) of the 1413 patients where on ≤4-years’ worth of 200mg OD equivalent 
amiodarone,  with the highest number of patients being on amiodarone for 1-years’ 
worth of 200mg OD equivalent (382, 27%) compared to just 20 (1.4%) patients on 
10-years’ worth of 200mg OD equivalent. There was is a positive correlation between 
amiodarone exposure and percentage of patients with an abnormal result (p < 
0.0005) within each year group, Fig. 23. The correlation between total exposure and 
percentage of patients with an abnormal result was is strongest in the first 4 years, 
with a 2.46-fold increase (4.7 to 11.6%) in percentage of patients between the first 
and fourth year of amiodarone therapy.  
 
Abnormal TSH 
1012 (72%) patients had a TSH baseline testing was performed on 1012 (72%) 
patients;. 33 patients had abnormal TSH at baseline and were removed from further 
analysis. Of the remaining patients not on thyroxine, 162 (16%) had at least one 
abnormal TSH, of which 125 (77%) had at least one TSH <0.4mU/L and 45 (28%) 
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had at least one TSH >10mU/L. The median number of days from starting 
amiodarone to first abnormal result was 434 (90-6832 days). The median number of 
days from starting amiodarone to a first suppressed TSH (defined as <0.4mU/L) was 
560 days (90-3761 days). The median number of days from starting amiodarone to a 
high TSH (defined as> 10mU/L) was 609 days (92-4586 days). 172 (17%) patients 
did not have TFT tested.  
Pharmacological intervention for Thyroid abnormalities 
140 (10%) patients were started on thyroxine at least 6 months following initiation of 
amiodarone. The median number of days between starting amiodarone to first 
thyroxine prescription was 686 days (range 182-6553 days). 40 (3%) patients were 
prescribed anti-hyperthyroid medication while on amiodarone. The median number of 
days between starting amiodarone to first anti-hyperthyroid prescription was 951days 
(range 182-1545 days). The incidence of thyroid abnormalities was, higher than the 
background population incidence in Tayside as reported in the TEARS study (Table 
32), with a relative 9.5 and 17.5 fold increase in the incidence of hypothyroidism and 
hyperthyroidism respectively 
Total exposure to amiodarone and abnormal TFT 
Fig. 23 shows the percentage of patients within each group that had a TSH result 
<0.4 or >10mU/L, and a positive correlation between years’ worth of amiodarone and 
percentage of patients with an abnormal results (p < 0.0005). The correlation 
between total exposure and percentage of patients with an abnormal result is 
strongest in the first 4 years, with a 2.5-fold increase (6-15%) in percentage of 
patients between the first and fourth year of amiodarone therapy.  
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Discussion 
The study provides an insight into the effect of amiodarone exposure and the attendant risks of 
ADRs. The results of this study show that a significant proportion of patients in the community are 
on amiodarone for considerably longer than one year and, importantly, the risk of LFT and TFT 
abnormalities increases with total exposure to amiodarone. Throughout the 22 years in Tayside 
that this project analysed, the majority of patients failed to have adequate monitoring in 
accordance with guidelines. Although monitoring improved significantly over the study period, it 
remained suboptimal with only 22.3% of patients being monitored adequately with comprehensive 
monitoring for both hepatic and thyroid dysfunction in the last 5-years of the study. Baseline 
testing was performed in only 68% of patients for ALT and 72% for TSH. As the prevalence of 
incidental abnormal ALT can be as high as 7.3%,(13), this highlights the need for more stringent 
baseline testing.  
 
In contrast to previous studies mostly in the USA, demonstrating poor monitoring, this is the 
largest and longest study investigating amiodarone monitoring in a public healthcare service. 
Raebel et al,(14), reported monitoring in 53.3% of 1055 patients over 10 Health Maintenance 
Organisations over a 6-month period. Bickford et al,(15), found monitoring rates of 35% and 20% 
for ALT and TSH respectively,(16). However, of 227 initially identified patients, only 45 patients 
were analysed. A further study assessing guideline development for monitoring of high risk 
medications, including amiodarone, found that 60% and 48% had LFT and TFT monitoring, 
respectively over a 13-month period,(17). Other studies have demonstrated low monitoring rates, 
from 23-42%, however their cohorts were of less than 100 patients,(18, 19). There are differences 
in the monitoring rates between Tayside and the USA, possibly related to differences in healthcare 
systems, but notably our study spans a 22-year era before and after guideline development and 
reports relatively contemporary data compared to previous studies.  
The median total exposure of amiodarone in our study was 1.95 years worth of 200mg OD. While 
previous papers have suggested that toxicity is less likely on amiodarone doses of 200mg 
daily,(5), our study found that total cumulative exposure of amiodarone is important, even at doses 
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equivalent to 200mg OD. It is worth noting that most studies reported on the effects of limited 
amiodarone exposure, over a relatively short time period, in contrast to ours. A prospective study 
of 125 patients over 5 years found than doses greater than 2.5mg/kg had a greater than 6% risk of 
deranged LFT’s,(20), however we found that at 4-years of amiodarone at 200mg OD, the risk of 
having an abnormal ALT test and TSH was increased 2.5 fold, to a prevalence of 11.6%. 
Our study highlights that there is a need to monitor patients for toxicity even with relatively low 
doses.  Indeed, 9.5% of patients in Tayside had at least one ALT result >3xULN and 17% of 
patients had abnormal TSH results. Goldschlager et al reported an incidence of 15-30% for ALT 
>2xULN,(16), compared with 12.3% of patients in our study. One possible explanation for the 
difference is underreporting, as that 12% of patients in Tayside never had ALT tested. Similarly 
with TSH, where 17% of thyroxine naïve patients never had TSH tested. A recent large cross 
sectional study investigating the prevalence of prescribing and monitoring in primary care in the 
UK found that 42.2% of patients did not have TFT monitoring within 6 months of their start date. 
The prevalence noted was higher than observed in our study; however reliability of the data 
(derived from the intra-class correlation coefficient) was low (0.47),(21). 
The clinical significance of biochemical abnormalities associated with amiodarone use is not clear. 
Raeder et al found that 52% of 217 patients developed ADRs after an average of 11.8 month of 
treatment, with 8.3% of patients discontinuing amiodarone. Only 19% of patients had clinically 
significant adverse effects, with clinical hepatitis accounting for 0.5%,(22).  Although this suggests 
that most patients develop only mild transaminitis, the longterm consequences of mild 
transaminitis with continued use of amiodarone are unknown and most of the studies reporting a 
low incidence of severe reactions, such as hepatitis, cirrhosis or death are in short term 
studies,(22-24). In addition, the risk of clinically significant hepatitis being missed remains. 
Ten percent of our study population required thyroxine treatment, while 3% developed overt 
hyperthyroidism, similar to a 612 patient sub-study of the SAFE-Trial, where 7% of study patients 
on amiodarone were prescribed levothyroxine with 5% of patients developed overt 
hyperthyroidism,(10). Nevertheless, the close monitoring of study subjects in the clinical trial 
program in contrast to the real world setting where 17% of patients on amiodarone never had 
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thyroid testing, resulting in cases thyroid dysfunction being possibly missed, suggests that there is 
a potential risk of underestimating thyroid dysfunction. Indeed, comparison with epidemiological 
data in Tayside,(13), indicates that the incidence of hypothyroidism and hyperthyroidism during 
amiodarone treatment is increased by 9.5 and 17.5 fold respectively (table 32) when compared to 
that of the background incidence,(12). The results also show that biochemical abnormalities 
indicative of hyperthyroidism while on amiodarone are more common than hypothyroidism, but 
clinically significant disease requiring pharmacological intervention is much lower.  
 
Our results demonstrate a direct correlation between length of exposure to amiodarone and 
abnormal biochemical results. Previous studies have shown small correlations with duration of 
treatment and ADRs,(22, 24). More recently, a large 12-year study of 930 patients found that 
duration of treatment was the only independent predictor of adverse effect (OR 1.21 per year, 
p=0.016),(25).   A previous meta-analysis of adverse effects of low dose amiodarone found the 
odds for hepatotoxicity was similar to that of the control group at 12 months,(2). Indeed, our data 
shows that ALT abnormalities do not commonly develop in the first year of 200mg daily 
amiodarone (4.7%), but importantly increases thereafter, with the number of patients with an 
abnormal ALT result increased 2.5-fold over the following 4-years’ worth of 200mg OD equivalent 
dosing.  
Previous studies have found that thyroid toxicity typically occurs in the first 24 months,(16). 
However, our study found that thyroid function abnormalities occurred later with the median 
number of days from starting amiodarone to biochemical hyperthyroidism and hypothyroidism 
being 560 days (90-3761 days) and 609 days (92-4586 days) respectively.  Yet, despite the small 
sample sizes in the increasing exposure years, our study shows that there is a continued increase 
in the incidence of thyroid toxicity in this reduced cohort.  
 
Limitations 
Being a retrospective linkage study, there were several limitations including lack of access to 
clinical data to correlate biochemical abnormalities. This may have resulted in over-estimating 
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ADRs as we were unable to identify other potential causes. We were also not able to determine 
the incidence of other amiodarone ADRs or the clinicians’ decision to continue or discontinue 
amiodarone, and reasons for poor monitoring. We included only incident thyroid disease by 
selecting patients diagnosed after 6-months on amiodarone, however, we were unable to exclude 
previous resolved thyroid disease. After 4-years’ worth of 200mg OD dosing exposure equivalent, 
the relationship with biochemical abnormalities was unpredictable, possibly because of the small 
number of patients with prolonged exposure, resulting in fewer person years follow-up, which may 
also limit the comparison of incidence of thyroid abnormalities using the TEARS data. 
 
Conclusion 
This retrospective study, which we believe to be the largest and longest follow up study of 
amiodarone monitoring in a public healthcare service, has identified the increasing risk of 
developing ADRs with continued exposure to amiodarone. Although the majority of these will be of 
minimal significance, there remains a risk of clinical significant ADRs being missed through poor 
adherence to monitoring guidance, highlighting the need for improved surveillance. While 
monitoring practice has improved in accordance with current guidelines, there is still a shortfall in 
achieving safe standards, which is of particular concern, as amiodarone remains the most widely 
prescribed anti-arrhythmic drug worldwide. Consideration of strategies to improve monitoring in 
patients who are prescribed amiodarone such as the introduction of a shared care protocol 
between primary and secondary care or computerised prescribing prompts, which have shown to 
be effective,(26), may reduce amiodarone-toxicity through education and active intervention. 
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Table 1. Baseline characteristics 
  n (%) patients 
Gender Male  811 (57.4%) 
 Female 602 (42.6%) 
Age Mean (SD) 71.3 (11.3) 
Dose/day 200mg 1003 (71.00) 
 <200mg 366 (26.0) 
 >200mg 44 (3.1) 
Indication for 
starting amiodarone 
AF 
VT 
SVT 
AF & VT 
Unspecified tachycardia 
No diagnosis 
 
952 (67.4) 
125 (8.8) 
39 (2.8) 
 45 (3.2) 
8 (0.6) 
244 (17.3) 
 
Duration of Therapy Median (days) 852 
 Minimum (days) 168  
 Maximum (days) 8,079  
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Table 2: Prescribing of amiodarone & biochemical monitoring in accordance with guidelines, split 
in 5-year groups. There is a significant increase in prescribing over the last 22-years from 7.5% to 
22.3% of patients being monitored in accordance with guidelines. (χ²=33.1, df=3, p<0.001)  
Years Total No. of 
patients 
No. of 
patients with 
1 ALT & TSH 
test 
No. of patients 
monitored in 
accordance with  
guidelines (%) 
1989-1994 186 56 14 (7.5) 
1994-2000 438 150 43 (9.8) 
2000-2005 489 225 87 (17.8) 
2005-2011 300 131 67 (22.3) 
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Table 32. Incidence of thyroid pharmacological intervention compared to the TEARS study 
 Patient 
characteristics 
Hypothyroidism Hyperthyroidism 
Age n/patient
s 
Person 
years 
follow-up 
TEARS 
incidence 
rate (per 
1000/year) 
Predicted 
incidence  
(per 
1000/year) 
 
Actual 
incidence  
(per 
1000/year) 
Relative 
increase  
TEARS 
incidence rate 
(per 
1000/year) 
Predicted 
incidence  
(per 
1000/year) 
Actual 
incidence  
(per 
1000/year) 
Relative 
increase 
Female           
60-69 113 444 9.06 4.03 7 1.74 1.12 0.50 1 2.01 
70-79 242 1002 8.84 8.86 32 3.61 1.29 1.29 11 8.51 
80+ 201 598 9.72 5.81 23 3.96 1.05 0.62 2 3.19 
Male           
60-69 251 897 1.78 1.60 21 13.15 0.27 0.24 12 49.5 
70-79 295 973 2.69 2.62 32 12.23 0.29 0.28 5 17.7 
80+ 124 316 4.85 1.53 11 7.17 0.45 0.14 0 - 
All cases 1413 4959 2.97 14.73 140 9.5 0.46 2.28 40 17.5 
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Figure Legends:  
 
Fig.1. Consort diagram depicting flow of study participants 
Fig. 2: Prescribing of amiodarone & biochemical monitoring in accordance with guidelines, split in 5-
year groups. There is a significant increase in prescribing over the last 22-years from 7.5% to 22.3% 
of patients being monitored in accordance with guidelines. (χ²=33.1, df=3, p<0.001)  
Fig 23. IncidenceRelationship of liver and thyroid abnormalities and for each years of amiodarone 
exposure, defined as equivalent exposure to 200mg/day per year 
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Fig.1. Consort diagram depicting flow of study participants  
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Fig 2. Incidence of liver and thyroid abnormalities for each year of amiodarone exposure, defined as 
equivalent exposure to 200mg/day per year  
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